Zeinab Barekati

Zeinab Barekati

Auto-generated profile, based on publicly available information

Zeinab Barekati

Laboratory for Gynecological Oncology, Women’s Hospital/Department of Biomedicine, University of Basel, Hebelstrasse 20, CH 4031, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2009 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
CKCorina Kohler
Corina Kohler
RRRamin Ramin Radpour
Ramin Ramin Radpour
ZBZeinab Barekati
Zeinab Barekati
RAReza Asadollahi
Reza Asadollahi
JBJohannes Bitzer
Johannes Bitzer
XZXiao Yan Zhong
Xiao Yan Zhong
Background: With the aim to simplify cancer management, cancer research lately dedicated itself more and more to discover and develop non-invasive biomarkers. In this connection, circulating cell-free DNA (ccf DNA) seems to be a promising candidate. Altered levels of ccf nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) have been found in several cancer types and might have a diagnostic value. Methods: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls. To evaluate the applicability of plasma ccf nDNA and mtDNA as a biomarker for distinguishing between the three study-groups we performed ROC (Receiver Operating Characteristic) curve analysis. We also compared the levels of both species in the cancer group with clinicopathological parameters. Results: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022). The level of ccf nDNA was also associated with tumor-size (2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034). Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001). Conclusion: Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management. However, ccf nDNA shows greater promise regarding sensitivity and specificity.

14 June 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZBZeinab Barekati
Zeinab Barekati
RRRamin Ramin Radpour
Ramin Ramin Radpour
QLQing Lu
Qing Lu
JBJohannes Bitzer
Johannes Bitzer
HZHong Zheng
Hong Zheng
XZXiao Yan Zhong
Xiao Yan Zhong
Invasion and metastasis are two important hallmarks of malignant tumors caused by complex genetic and epigenetic alterations. The present study investigated the contribution of aberrant methylation profiles of cancer related genes, APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P14 (ARF), P16 (CDKN2A), P21 (CDKN1A), PTEN, and TIMP3, in the matched axillary lymph node metastasis in comparison to the primary tumor tissue and the adjacent normal tissue from the same breast cancer patients to identify the potential of candidate genes methylation as metastatic markers.

1 August 2011
Verified
Journal Article
Closed access
CKCorina Kohler
Corina Kohler
ZBZeinab Barekati
Zeinab Barekati
RRRamin Ramin Radpour
Ramin Ramin Radpour
XZXiao Yan Zhong
Xiao Yan Zhong

1 January 2010
Verified
Journal Article
Closed access
BZBei Zhang
Bei Zhang
ZBZeinab Barekati
Zeinab Barekati
CKCorina Kohler
Corina Kohler
RRRamin Ramin Radpour
Ramin Ramin Radpour
RAReza Asadollahi
Reza Asadollahi
XZXiao Yan Zhong
Xiao Yan Zhong

1 December 2011
Verified
Journal Article
Closed access
FCFeng Feng Cai
Feng Feng Cai
CKCorina Kohler
Corina Kohler
BZBei Zhang
Bei Zhang
WCWei Jie Chen
Wei Jie Chen
ZBZeinab Barekati
Zeinab Barekati
XZXiao Yan Zhong
Xiao Yan Zhong

21 June 2011 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CKCorina Kohler
Corina Kohler
BTBjörn Tavelin
Björn Tavelin
AFAlex Xiu-Cheng Fan
Alex Xiu-Cheng Fan
RRRamin Ramin Radpour
Ramin Ramin Radpour
ZBZeinab Barekati
Zeinab Barekati
PTPaolo Toniolo
Paolo Toniolo